Araie Makoto
Department of Ophthalmology, The University of Tokyo Graduate School of Medicine, Japan.
Nippon Ganka Gakkai Zasshi. 2011 Mar;115(3):213-36; discussion 237.
Pathogenesis of open-angle glaucoma involves both pressure-dependent damaging factors and pressure-independent damaging factors. The high prevalence of open-angle glaucoma with normal pressure (normal-tension glaucoma) in Japan implies that treatment of pressure-independent damaging factors in Japanese open-angle glaucoma patients is of importance. In an attempt to investigate the roles of pressure-independent damaging factors in open-angle glaucoma, we carried out basic and clinical studies and obtained the following results. 1. The rate of deterioration of visual field after trabeculectomy in normal tension glaucoma patients with post-operative intraocular pressure (IOP) of 10 mmHg was found to be -0.25 dB/year of mean deviation (MD), suggesting that contribution of pressure-independent damaging factors to the deterioration of MD in open-angle glaucoma is around -0.25 dB/year of mean deviation (MD). 2. Experiments using isolated purified cultured retinal ganglion cells (RGCs) indicated that calcium-channel blockers and some of antiglaucoma drugs showed neuroprotective effects on RGCs at concentrations of 0.01 microM or higher. 3. In mice, damage to RGCs resulted in secondary degeneration of neurons and activation of glial cells in the lateral geniculate nucleous (LGN) and superior colliculus, and these secondary changes in the central nervous system (CNS) due to RGC damage was partly ameliorated by systemic administration of memantine. 4. Mice experimental high IOP glaucoma models could be established using laser irradiation of the limbal area, and the usefulness of Tonolab in IOP measurements of mice eye was confirmed. 5. Monkey experimental high IOP glaucoma models revealed that in the glaucomatous optic nerve head vaso-constrictive reactions to an alpha-1 agonist was abolished, while vasodilative reaction to a prostaglandin FP receptor agonist was retained. 6. In monkeys with experimental high IOP glaucoma, secondary damage to neurons in the LGN and the glial reaction to it were also found, similar to the mice experiments. In living monkeys the glial reaction in the LGN could be observed by means of positron emission tomography. 7. In the LGN of monkeys with experimental high IOP glaucoma, the M-cell system was preferentially damaged in the early stage, while in the later stages both the M- and P-cell systems were damaged. 8. In a single-instituted prospective double-blinded clinical trial, oral administration of nilvadipine at 4 mg/day, a DHP calcium-channel blocker, was found to significantly retard the visual field progression in normal tension glaucoma patients over 3 years, while significantly increasing the choroidal and optic nerve blood flow by about 35%. 9. A multi-instituted prospective double-blinded clinical trial in normal tension glaucoma patients revealed that the rate of MD deterioration under monotherapy with either topical nipradilol or timolol was around -0.05 dB/year, thought to be considerably slower than -0.25 dB/year, the commonly estimated rate of MD deterioration by pressure-independent damaging factors. The current results indicate the possibility of treatment of pressure-independent damaging factors of open-angle glaucoma in Japanese open-angle glaucoma patients with oral nilvadipine and topical anti-glaucoma agents.
开角型青光眼的发病机制涉及眼压依赖性损害因素和眼压非依赖性损害因素。日本正常眼压性开角型青光眼(正常眼压性青光眼)的高患病率表明,治疗日本开角型青光眼患者的眼压非依赖性损害因素至关重要。为了研究眼压非依赖性损害因素在开角型青光眼中的作用,我们进行了基础和临床研究,并获得了以下结果。1. 眼压为10 mmHg的正常眼压性青光眼患者小梁切除术后视野恶化率为平均偏差(MD)每年-0.25 dB,这表明眼压非依赖性损害因素对开角型青光眼MD恶化的贡献约为平均偏差(MD)每年-0.25 dB。2. 使用分离纯化的培养视网膜神经节细胞(RGCs)进行的实验表明,钙通道阻滞剂和一些抗青光眼药物在浓度为0.01 microM或更高时对RGCs具有神经保护作用。3. 在小鼠中,RGCs损伤导致外侧膝状体核(LGN)和上丘神经元的继发性变性和胶质细胞活化,而美金刚全身给药可部分改善RGCs损伤引起的中枢神经系统(CNS)的这些继发性变化。4. 利用激光照射角膜缘区域可建立小鼠实验性高眼压青光眼模型,并证实Tonolab在测量小鼠眼压方面的有效性。5. 猴实验性高眼压青光眼模型显示,青光眼性视神经乳头对α-1激动剂的血管收缩反应消失,而对前列腺素FP受体激动剂的血管舒张反应保留。6. 在实验性高眼压青光眼的猴中,也发现了LGN中神经元的继发性损伤及其胶质反应,类似于小鼠实验。在活体猴中,可通过正电子发射断层扫描观察LGN中的胶质反应。7. 在实验性高眼压青光眼的猴的LGN中,M细胞系统在早期优先受损,而在后期M细胞和P细胞系统均受损。8. 在一项单机构前瞻性双盲临床试验中,发现每天口服4 mg尼伐地平(一种二氢吡啶类钙通道阻滞剂)可显著延缓正常眼压性青光眼患者3年的视野进展,同时使脉络膜和视神经血流量显著增加约35%。9. 一项针对正常眼压性青光眼患者的多机构前瞻性双盲临床试验显示,局部使用尼普地洛或噻吗洛尔单药治疗时MD恶化率约为每年-0.05 dB,认为比通常估计的眼压非依赖性损害因素导致的MD恶化率每年-0.25 dB要慢得多。目前的结果表明,口服尼伐地平和局部使用抗青光眼药物有可能治疗日本开角型青光眼患者的眼压非依赖性损害因素。